Sugi Predict

Sugi Predict / Compounds / SCHEMBL3841527

SCHEMBL3841527

SCHEMBL3841527

Nc1ncnc2c1N(F)CN2[C@@H]1O[C@H](CO)C(O)C1O

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ DOT1L Q8TEK3 3/20 0.50
▸ MAPK1 P28482 3/20 0.50
▸ HIF1A Q16665 2/20 0.50
▸ STAT6 P42226 2/20 0.50
▸ DPP4 P27487 1/20 0.50
▸ MEN1 O00255 1/20 0.50
▸ SLC28A1 O00337 1/20 0.50
▸ MAP3K7 O43318 1/20 0.50
▸ SLC28A2 O43868 1/20 0.50
▸ GAPDH P04406 1/20 0.50
▸ ADORA3 P0DMS8 1/20 0.50
▸ ADORA2A P29274 1/20 0.50
▸ ADORA2B P29275 1/20 0.50
▸ ADORA1 P30542 1/20 0.50
▸ PI4KA P42356 1/20 0.50
▸ KMT2A Q03164 1/20 0.50
▸ SMN1; SMN2 Q16637 1/20 0.50
▸ PI4K2B Q8TCG2 1/20 0.50
▸ SLC29A1 Q99808 1/20 0.50
▸ PI4K2A Q9BTU6 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27767961 1.00 DOT1L (0.50) DOT1LMAPK1HIF1ASTAT6DPP4
SCHEMBL1375287 0.87 MEN1 (0.42) DOT1LMAPK1HIF1ASTAT6DPP4
SCHEMBL15973691 0.86 ADK (0.50) DOT1LMAPK1HIF1ASTAT6DPP4
SCHEMBL830796 0.86 MAPK1 (0.50) DOT1LMAPK1HIF1ASTAT6DPP4
SCHEMBL1936244 0.86 ADK (0.50) DOT1LMAPK1HIF1ASTAT6DPP4
SCHEMBL1666083 0.86 HSPA5 (0.52) DOT1LMAPK1HIF1ASTAT6DPP4
SCHEMBL1936249 0.86 ADK (0.50) DOT1LMAPK1HIF1ASTAT6DPP4
SCHEMBL724943 0.86 MAPK1 (0.50) DOT1LMAPK1HIF1ASTAT6DPP4
SCHEMBL830795 0.86 MAPK1 (0.50) DOT1LMAPK1HIF1ASTAT6DPP4
Ammonia Solution, Strong SCHEMBL28844518 0.85 HSPA5 (0.51) DOT1LMAPK1HIF1ASTAT6DPP4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9694028-B2 4′-azido, 3′-deoxy-3′-fluoro substituted nucleoside derivatives as inhibitors of HCV RNA replication RIBOSCIENCE LLC (US) 2017-07-04 — — US claimed
US-20160220596-A1 4'-AZIDO, 3'-DEOXY-3'-FLUORO SUBSTITUTED NUCLEOSIDE DERIVATIVES AS INHIBITORS OF HCV RNA REPLICATION RIBOSCIENCE LLC 2016-08-04 — — US claimed
EP-2996696-A1 4'-AZIDO, 3'-DEOXY-3'-FLUORO SUBSTITUTED NUCLEOSIDE DERIVATIVES Riboscience LLC (US) 2016-03-23 — — EP claimed
US-9249176-B2 4′-azido, 3′-deoxy-3′-fluoro substituted nucleoside derivatives as inhibitors of HCV RNA replication RIBOSCIENCE LLC (US) 2016-02-02 — — US claimed
WO-2014193663-A1 4'-AZIDO, 3'-DEOXY-3'-FLUORO SUBSTITUTED NUCLEOSIDE DERIVATIVES RIBOSCIENCE LLC (US) 2014-12-04 — — WO claimed
US-20140341848-A1 4'-AZIDO, 3'-DEOXY-3'-FLUORO SUBSTITUTED NUCLEOSIDE DERIVATIVES AS INHIBITORS OF HCV RNA REPLICATION RIBOSCIENCE LLC (US) 2014-11-20 — — US claimed
US-9694028-B2 4′-azido, 3′-deoxy-3′-fluoro substituted nucleoside derivatives as inhibitors of HCV RNA replication RIBOSCIENCE LLC (US) 2017-07-04 — — US disclosed
US-20160220596-A1 4'-AZIDO, 3'-DEOXY-3'-FLUORO SUBSTITUTED NUCLEOSIDE DERIVATIVES AS INHIBITORS OF HCV RNA REPLICATION RIBOSCIENCE LLC 2016-08-04 — — US disclosed
EP-2996696-A1 4'-AZIDO, 3'-DEOXY-3'-FLUORO SUBSTITUTED NUCLEOSIDE DERIVATIVES Riboscience LLC (US) 2016-03-23 — — EP disclosed
US-9249176-B2 4′-azido, 3′-deoxy-3′-fluoro substituted nucleoside derivatives as inhibitors of HCV RNA replication RIBOSCIENCE LLC (US) 2016-02-02 — — US disclosed
WO-2014193663-A1 4'-AZIDO, 3'-DEOXY-3'-FLUORO SUBSTITUTED NUCLEOSIDE DERIVATIVES RIBOSCIENCE LLC (US) 2014-12-04 — — WO disclosed
US-20140341848-A1 4'-AZIDO, 3'-DEOXY-3'-FLUORO SUBSTITUTED NUCLEOSIDE DERIVATIVES AS INHIBITORS OF HCV RNA REPLICATION RIBOSCIENCE LLC (US) 2014-11-20 — — US disclosed
EP-1804812-A4 FLUORINATED PYRROLOÝ2,3-D¨PYRIMIDINE NUCLEOSIDES FOR THE TREATMENT OF RNA-DEPENDENT RNA VIRAL INFECTION MERCK & CO INC (US) 2009-09-02 — — EP disclosed
US-20080280842-A1 Fluorinated Pyrrolo[2,3-D]Pyrimidine Nucleosides for the Treatment of Rna-Dependent Rna Viral Infection MERCK & CO., INC. (US) 2008-11-13 — — US disclosed
EP-1804812-A2 FLUORINATED PYRROLOÝ2,3-D¨PYRIMIDINE NUCLEOSIDES FOR THE TREATMENT OF RNA-DEPENDENT RNA VIRAL INFECTION Merck & Co., Inc. (US) 2007-07-11 — — EP disclosed
WO-2006065335-A2 FLUORINATED PYRROLO[2,3-D]PYRIMIDINE NUCLEOSIDES FOR THE TREATMENT OF RNA-DEPENDENT RNA VIRAL INFECTION MERCK & CO., INC. (US) 2006-06-22 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160220596-A1 4'-AZIDO, 3'-DEOXY-3'-FLUORO SUBSTITUTED NUCLEOSIDE DERIVATIVES AS INHIBITORS OF HCV RNA REPLICATION EIF2AK2, NSUN2, RNGTT DOT1L 2219/4885MAPK1 2741/4885HIF1A 3308/4885
US-20140341848-A1 4'-AZIDO, 3'-DEOXY-3'-FLUORO SUBSTITUTED NUCLEOSIDE DERIVATIVES AS INHIBITORS OF HCV RNA REPLICATION EIF2AK2, NSUN2, RNGTT DOT1L 2219/4885MAPK1 2741/4885HIF1A 3308/4885
US-20080280842-A1 Fluorinated Pyrrolo[2,3-D]Pyrimidine Nucleosides for the Treatment of Rna-Dependent Rna Viral Infection NSUN2, DUT, EFTUD2 DOT1L 2133/4885MAPK1 3938/4885HIF1A 3414/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.